Evidence map›Paper›PMID 30547049›Full record

ArticleMolecular therapy. Methods & clinical development2018

Lentiviral Vector Purification Using Genetically Encoded Biotin Mimic in Packaging Cell.

Leila Mekkaoui, Farhaan Parekh, Ekaterini Kotsopoulou, David Darling, Glenda Dickson, Gordon W Cheung, Lucas Chan, Kirsty MacLellan-Gibson, Giada Mattiuzzo, Farzin Farzaneh and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Implementation of Novel Affinity Ligand for Lentiviral Vector Purification.International journal of molecular sciences · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Laboratory-Scale Lentiviral Vector Production and Purification for EnhancedMolecular therapy. Methods & clinical development · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Leila MekkaouiUCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
Farhaan ParekhUCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
Ekaterini KotsopoulouAutolus Limited, Forest House, 58 Wood Lane, London W12 7RZ, UK.
David DarlingSchool of Cancer & Pharmaceutical Sciences, King's College London, Molecular Medicine Group, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.
Glenda DicksonSchool of Cancer & Pharmaceutical Sciences, King's College London, Molecular Medicine Group, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.
Gordon W CheungUCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
Lucas ChanSchool of Cancer & Pharmaceutical Sciences, King's College London, Molecular Medicine Group, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.
Kirsty MacLellan-GibsonNational Institute for Biological Standards and Control-MHRA, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QC, UK.
Giada MattiuzzoNational Institute for Biological Standards and Control-MHRA, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QC, UK.
Farzin FarzanehSchool of Cancer & Pharmaceutical Sciences, King's College London, Molecular Medicine Group, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.
Yasuhiro TakeuchiNational Institute for Biological Standards and Control-MHRA, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QC, UK.
Martin PuleUCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
King's College London · GBUniversity College London · GBNational Institute for Biological Standards and Control · GBAutolus (United Kingdom) · GB

Funding

Biotechnology and Biological Sciences Research Council BB/D014301/1Biotechnology and Biological Sciences Research Council BB/E005896/1
6 · The paper itself

Abstract

Lentiviral vectors (LVs) have recently witnessed an increasing demand in research and clinical applications. Their current purification processes represent the main bottleneck in their widespread use, as the methods used are cumbersome and yield low recoveries. We aimed to develop a one-step method to specifically purify LVs, with high yields and reduced levels of impurities, using the biotin-streptavidin system. Herein, packaging HEK293T cells were genetically engineered with a cyclical biotin-mimicking peptide displayed on a CD8α stalk, termed cTag8. LVs were modified with cTag8 by its passive incorporation onto viral surfaces during budding, without viral protein engineering or hindrance on infectivity. Expression of cTag8 on LVs allowed complete capture of infectious particles by streptavidin magnetic beads. As cTag8 binds streptavidin in the nanomolar range, the addition of micromolar concentrations of biotin resulted in the release of captured LVs by competitive elution, with overall yields of ≥60%. Analysis of eluted LVs revealed high purity with a >3-log and 2-log reduction in DNA contamination and host cell proteins, respectively. This one-step purification was also tested for scalable vector processing using monolith affinity chromatography, with an encouraging preliminary overall yield of 20%. This method will be of valuable use for both research and clinical applications of LVs.

Indexed as

affinity chromatographybiotin mimiccompetitive elutionlentiviral vectorspurificationstreptavidinsynthetic peptide

Identifiers

PMID30547049
PMCPMC6258877
OpenAlexW2895822398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.